Evidence map›Paper›PMID 39464957›Full record

ArticleJournal of family medicine and primary care2024

Dapsone-induced haemolysis among leprosy patients on MDT from an endemic area of central India.

Krutika P Naik, Satyaki Ganguly, Arvind K Shukla, Namrata Chhabra, Neel Prabha, Ghazal Ahmed

Abstract read
In one paragraph

Article in Journal of family medicine and primary care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Krutika P NaikDepartment of Dermatology, Venereology and Leprosy, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Satyaki GangulyDepartment of Dermatology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Arvind K ShuklaDepartment of Community and Family Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Namrata ChhabraDepartment of Dermatology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Neel PrabhaDepartment of Dermatology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Ghazal AhmedDepartment of Dermatology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: Haemolysis due to dapsone as a part of MDT in leprosy patients has been long recognized. However, the frequency and severity of this side effect and factors associated with it have not been well documented. We planned to determine the frequency of dapsone-induced haemolysis in leprosy patients on MDT and various risk factors associated with it. Materials and Methods: This was a hospital-based retrospective analysis, conducted on 36 treatment completed or partially treated or on treatment leprosy patients in a tertiary care centre in Chhattisgarh. Results: Out of 36 patients, 83.3% showed a fall in haemoglobin from the baseline value (pre-treatment values). Dapsone was stopped in 33.3% of patients with a significant fall in haemoglobin. We found that the mean haemoglobin concentration for all patients fell from 13.05(+/-1.8) g/dl to 11.8(+/-1.9) g/dl ( Conclusion: Our results underline the need to incorporate haematological investigations in leprosy management protocol, especially in primary care settings where the majority of leprosy patients are managed.

Indexed as

Dapsonehaemolysisleprosy

Identifiers

PMID39464957
PMCPMC11504738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.